Covalon Technologies Ltd V.COV

CLABS

[prophetoffactz]

Jan

 

@buss_jan

·

Mar 24

 

 

The numbers: • 10M central lines used/year → 250k infections, 38k deaths • 200M peripheral lines used/year → 360k infections, 46k deaths Massive opportunity in a critical area of health care

 

1

 

 

 

1

 

61

 

 

 

 

 

 

 

 

 

 

 

 

Jan

 

@buss_jan

·

Mar 24

 

 

Covalon believes there’s a $2.5B market opportunity here. By applying proven CLABSI protocols to peripheral lines (PLABSI). They’re currently in less than 10% of U.S. hospitals and have already added 20 new hospitals this year.

 

 

 

 

Jan

 

@buss_jan

 

 

Biggest take away from Covalons $cvalf $cov.v AGM is the huge potential management sees in CLABSI (central line–associated bloodstream infections) market.

 

 

 

 

Jan

 

@buss_jan

 

 

Biggest take away from Covalons $cvalf $cov.v AGM is the huge potential management sees in CLABSI (central line–associated bloodstream infections) market.